Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.30 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14736169 | 1.00 | MAPT (0.41) | MAPTNSD2ALDH1A1EGFRLMNA | |
| SCHEMBL19469287 | 0.96 | NSD2 (0.38) | MAPTNSD2ALDH1A1EGFRLMNA | |
| SCHEMBL14117087 | 0.92 | LMNA (0.37) | MAPTNSD2ALDH1A1EGFRLMNA | |
| SCHEMBL17606883 | 0.91 | MAPK1 (0.40) | MAPTNSD2ALDH1A1EGFRLMNA | |
| SCHEMBL27042345 | 0.90 | NSD2 (0.40) | MAPTNSD2ALDH1A1EGFRLMNA | |
| SCHEMBL32667778 | 0.90 | NSD2 (0.40) | MAPTNSD2ALDH1A1EGFRLMNA | |
| SCHEMBL29353225 | 0.88 | HTR6 (0.36) | MAPTNSD2ALDH1A1EGFRLMNA | |
| SCHEMBL29354371 | 0.88 | HTR6 (0.36) | MAPTNSD2ALDH1A1EGFRLMNA | |
| SCHEMBL21788 | 0.88 | HTR6 (0.36) | MAPTNSD2ALDH1A1EGFRLMNA | |
| SCHEMBL4988734 | 0.86 | HTR6 (0.34) | MAPTNSD2ALDH1A1EGFRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 629 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062374-A1 | PROCESS FOR THE PREPARATION OF A BENZENE DERIVATIVE | MELETIOS THERAPEUTICS (FR) | 2026-03-05 | — | — | US | claimed |
| US-20250388564-A1 | METHODS OF MANUFACTURING PYRIDAZINONE COMPOUNDS | EDGEWISE THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | claimed |
| EP-4594306-A1 | SYNTHESIS METHODS AND INTERMEDIATES FOR THE PRODUCTION OF REMIBRUTINIB | Novartis AG (CH) | 2025-08-06 | — | — | EP | claimed |
| EP-4568984-A1 | PROCESS FOR MANUFACTURING AN ANTIBIOTIC MACROCYCLIC PEPTIDE | F. Hoffmann-La Roche AG (CH) | 2025-06-18 | — | — | EP | claimed |
| CN-119998265-A | Synthetic methods and intermediates for the production of rebaudinib | 诺华股份有限公司 | 2025-05-13 | — | — | CN | claimed |
| CN-119677765-A | Method for producing antibiotic macrocyclic peptides | 豪夫迈·罗氏有限公司 | 2025-03-21 | — | — | CN | claimed |
| EP-4522599-A1 | METHODS OF MANUFACTURING PYRIDAZINONE COMPOUNDS | EDGEWISE THERAPEUTICS, INC. (US) | 2025-03-19 | — | — | EP | claimed |
| CN-119317621-A | Process for preparing pyridazinone compounds | 艾知怀斯治疗学公司 | 2025-01-14 | — | — | CN | claimed |
| EP-4038071-B1 | PROCESS FOR PREPARING AN ACTIVIN RECEPTOR-LIKE KINASE INHIBITOR | BLUEPRINT MEDICINES CORP (US) | 2024-12-18 | — | — | EP | claimed |
| US-20240300922-A1 | PROCESS FOR PREPARING EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2024-09-12 | — | — | US | claimed |
| WO-2023220180-A1 | METHODS OF MANUFACTURING PYRIDAZINONE COMPOUNDS | EDGEWISE THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | claimed |
| EP-4267591-A2 | ORGANOMETALLIC COMPOUNDS | Umicore AG & Co. KG (DE) | 2023-11-01 | — | — | EP | claimed |
| CN-116802187-A | Organometallic compounds | 优米科尔股份公司及两合公司 | 2023-09-22 | — | — | CN | claimed |
| CN-116655634-A | N6 chiral cyclic compound and preparation method and application thereof | 中国科学院化学研究所 | 2023-08-29 | — | — | CN | claimed |
| WO-2023102255-A1 | PEPTIDE-ENCODED LIBRARIES OF SMALL MOLECULES FOR DE NOVO DRUG DISCOVERY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-06-08 | — | — | WO | claimed |
| WO-2022271801-A1 | PROCESS FOR PREPARING EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2022-12-29 | — | — | WO | claimed |
| US-20220396576-A1 | PROCESS FOR PREPARING AN ACTIVIN RECEPTOR-LIKE KINASE INHIBITOR | BLUEPRINT MEDICINES CORPORATION | 2022-12-15 | — | — | US | claimed |
| EP-4038071-A1 | PROCESS FOR PREPARING AN ACTIVIN RECEPTOR-LIKE KINASE INHIBITOR | Blueprint Medicines Corporation (US) | 2022-08-10 | — | — | EP | claimed |
| WO-2022136049-A2 | ORGANOMETALLIC COMPOUNDS | UMICORE AG & CO. KG (DE) | 2022-06-30 | — | — | WO | claimed |
| CN-114502558-A | Method for preparing activin receptor-like kinase inhibitors | 缆图药品公司 | 2022-05-13 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062374-A1 | PROCESS FOR THE PREPARATION OF A BENZENE DERIVATIVE | BRDT, CYP3A7, TP53 | MAPT 4692/4885NSD2 2996/4885ALDH1A1 962/4885 |
| US-20250388564-A1 | METHODS OF MANUFACTURING PYRIDAZINONE COMPOUNDS | MUSK, SMN1; SMN2, PAX3 | MAPT 4814/4885NSD2 2958/4885ALDH1A1 469/4885 |
| US-20240300922-A1 | PROCESS FOR PREPARING EGFR INHIBITORS | EGFR, ERBB2, ERBB4 | MAPT 2551/4885NSD2 4179/4885ALDH1A1 2197/4885 |
| US-20220396576-A1 | PROCESS FOR PREPARING AN ACTIVIN RECEPTOR-LIKE KINASE INHIBITOR | ACVR1, ACVRL1, BMP2K | MAPT 4632/4885NSD2 4360/4885ALDH1A1 3481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.